+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis



Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis



Prostaglandins Leukotrienes and Essential Fatty Acids 77(5-6): 309-318



Specific fatty acid alterations have been described in the blood and tissues of cystic fibrosis (CF) patients. The two most consistent alterations include decreased levels of linoleic acid (LA) and decreased levels of docosahexaenoic acid (DHA). Increased arachidonic acid (AA) release from membrane phospholipids, as well as changes in levels of AA and other monounsaturated and polyunsaturated fatty acids (PUFAs) have also been described in CF. Although mechanisms of fatty acid alterations have not yet been determined, these alterations may have an important role in the progression of the CF disease. There have been several clinical trials in which CF patients were supplemented with n-3 fatty acids. Most trials resulted in an increase in the levels of the supplemental fatty acids in the blood of CF patients in the absence of significant clinical improvement. It is recommended that future trials include a larger population of CF patients and measure multiple clinical outcomes.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 021024540

Download citation: RISBibTeXText

PMID: 18036797

DOI: 10.1016/j.plefa.2007.10.009


Related references

Polyunsaturated fatty acid supplementation reverses cystic fibrosis-related fatty acid abnormalities in CFTR-/- mice by suppressing fatty acid desaturases. Journal of Nutritional Biochemistry 26(1): 36-43, 2015

Fatty acid supplementation in cystic fibrosis. Monographs in Paediatrics 10: 1-4, 1979

Is there a case for n-3 fatty acid supplementation in cystic fibrosis?. Current Opinion in Clinical Nutrition and Metabolic Care 8(2): 153-159, 2005

A therapeutic trial of fatty acid supplementation in cystic fibrosis. Pediatrics 57(4): 474-479, 1976

Long chain fatty acid metabolism and essential fatty acid deficiency with special emphasis on cystic fibrosis. Bracco, U. And R. J. Deckelbaum (ed.). Nestle Nutrition Workshop Series, Vol. 28. Polyunsaturated Fatty Acids In Human Nutrition; Meeting, Mexico City, Mexico, November 27-30,. Xi 243p. Nestec Ltd: Vevey, Switzerland; Raven Press: New York, New York, Usa. Illus. 159-167, 1992

Essential fatty acid deficiency and nutritional supplementation in cystic fibrosis. Journal of Pediatrics 141(2): 157-159, 2002

Evaluation of the Quantitative and Qualitative Alterations in the Fatty Acid Contents of the Sebum of Patients with Inflammatory Acne during Treatment with Systemic Lymecycline and/or Oral Fatty Acid Supplementation. Dermatology Research and Practice 2013: 120475, 2013

Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation. American Journal of Clinical Nutrition 34(1): 1-7, 1981

Effect on renal function of essential fatty acid supplementation in cystic fibrosis. Journal of Pediatrics 115(2): 242-250, 1989

Prospective study of fatty acid supplementation over 3 years in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2(3): 434-438, 1983

Effects of essential fatty acid deficiency and supplementation with docosahexaenoic acid (DHA; 22:6n-3) on cellular fatty acid compositions and fatty acyl desaturation in a cell culture model. Prostaglandins Leukotrienes and Essential Fatty Acids 64(1): 11-22, 2001

Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis. Liver. 14(1): 32-36, 1994

Negative effects of oral fatty acid supplementation on sweat chloride in cystic fibrosis. Pediatrics 64(1): 50-52, 1979

Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. Journal of Cystic Fibrosis 5(2): 77-84, 2006